Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.82 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8219783 | 0.90 | ELANE (0.66) | ELANECCR1MEN1KMT2A | |
| SCHEMBL2273394 | 0.90 | ELANE (1.00) | ELANECCR1MEN1KMT2A | |
| SCHEMBL27872087 | 0.90 | ELANE (0.82) | ELANECCR1MEN1KMT2A | |
| SCHEMBL1604508 | 0.89 | ELANE (0.81) | ELANECCR1MEN1KMT2A | |
| SCHEMBL14922185 | 0.89 | ELANE (0.81) | ELANECCR1MEN1KMT2A | |
| SCHEMBL1603715 | 0.88 | ELANE (0.72) | ELANECCR1MEN1KMT2A | |
| SCHEMBL1604631 | 0.88 | ELANE (0.80) | ELANECCR1MEN1KMT2A | |
| SCHEMBL14922184 | 0.88 | ELANE (0.80) | ELANECCR1MEN1KMT2A | |
| SCHEMBL1604898 | 0.88 | ELANE (0.78) | ELANECCR1MEN1KMT2A | |
| SCHEMBL17378390 | 0.88 | ELANE (0.83) | ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | claimed |
| US-10201536-B2 | Methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-12 | — | — | US | disclosed |
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2018-05-24 | — | — | US | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | disclosed |
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201536-B2 | Methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis | TLR8, TLR7, TLR3 | ELANE 99/4885CCR1 144/4885MEN1 4758/4885 |
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | TLR8, TLR7, TLR3 | ELANE 99/4885CCR1 144/4885MEN1 4758/4885 |
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | SERPINB1, ELANE, MPO | ELANE 2/4885CCR1 298/4885MEN1 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.